Analysis of Gut Microbiota in Stroke

The gut microbiota is an important intestinal microecosystem that plays an important role in maintaining homeostasis of the internal environment. A growing body of evidence supports the role of the gut and its microbiota in stroke, stroke prognosis, and recovery. The gut microbiota increases the risk of cerebrovascular events and plays a role in the development of stroke. Conversely, stroke causes dysregulation of the gut microbiota and epithelial barrier integrity. Modulation of the gut microbiota may provide novel therapeutic strategies for the treatment and prevention of stroke.

Fig. 1. Gut microbiota and stroke pathogenesis. (Yamashiro et al., 2021)

Our Services

Ace Therapeutics offers comprehensive services to help clients analyze the role of the gut microbiota, microbiome, and microbiota-derived metabolites in experimental stroke, and identify them as therapeutic targets for stroke. Our team consists of experts from various disciplines, including neuroscience, microbiology, genetics, and bioinformatics. By integrating knowledge from multiple fields, we provide reliable data on the complex interactions between the gut microbiota and stroke.

Analysis of the Microbiota-Gut-Brain Axis in Ischemic Stroke

We analyze use real-time quantitative PCR, fluorescence in situ hybridization, denaturing gradient gel electrophoresis, terminal restriction fragment length polymorphism, second-generation sequencing, macro-genomics, metabolomics, and 16S rRNA sequencing to analyze the gut microbiota (e.g. Roseburia, Bacteroides, Lachnospiraceae, Faecalibacteria, Blautia, Anaerostipes.) in germ-free (GF) animal models of stroke. GF mice can be colonized with specific strains or transplanted with feces, antibiotics or probiotics. These methods provide the differences in various physiological indicators and behavior of mice after different interventions.

Developing Gut Microbiota Modulation as a Therapeutic Strategy for Stroke

We are committed to analyzing the causal relationship between specific gut microbiota and stroke, and help clients to develop drugs (bacterial metabolites, small molecule modulators, and peptide drugs) that effectively modulate gut microbiota to provide theoretical support for gut microbiota modulation for stroke prevention or treatment. We offer the following experiments to help our clients develop stroke drugs that target gut microbiota.

• Fecal microbiota transplantation (FMT): Gut microbes extracted from normal mouse feces are transplanted into the intestines of ischemic stroke mice through different preparation processes and evaluated for long-term functional prognosis and survival.
• Strain formulation: Isolating bacteria one by one through AI computing and functional screening to create strain combinations for stroke treatment.
• Artificial modification of bacteria to enhance their medicinal functions using synthetic biology and genetic engineering methods.

Ace Therapeutics aims to help clients develop stroke drugs through the use of high-throughput sequencing of gut microbial genomes. We conduct rigorously designed prospective longitudinal studies to meet clients' needs. Through our comprehensive analysis services, multidisciplinary approach, and state-of-the-art facilities, we strive to be your trusted partner. Contact us to advance your stroke program!

1. Yamashiro, K., et al. (2021). Role of the gut microbiota in stroke pathogenesis and potential therapeutic implications. Annals of Nutrition and Metabolism, 77(Suppl. 2), 36-44.